NL-OMON30815尚未招募不适用
The effect of sorafenib (Bay-43-9006) on 111Indium labeled chimeric monoclonal antibody G250 or 111Indium labeled bevacizumab uptake in patients with clear cell RCC (ccRCC). - effect of sorafenib on imaging of ccRCC
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Renal cell carcinoma patients planned for surgery (nephrectomy/metastectomy)
- •-Karnofsky > 60 %
- •-age over 18 years
- •-signed informed consent
排除标准
- •-Known subtype other than clear cell RCC
- •-Pre-exposure to murine/chimeric antibody therapy
- •-Chemotherapy, immunotherapy or radiation therapy within 4 weeks prior to start of study. Palliative limited field external radiation for fracture prevention is allowed
- •-Diabetes Mellitus
研究者
相似试验
已完成
不适用
Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250Clear Cell Renal Cell CarcinomaNCT00602862Radboud University Medical Center26
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-PLMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma - SORAMICCarcinoma hepatocelular (CHC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 12.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableMedDRA version: 12.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularEUCTR2009-012576-27-SIMedical Faculty, University Magdeburg665
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)EUCTR2009-012576-27-ATMedical Faculty, University Magdeburg710
进行中（未招募）
1 期
Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA (Primovist) enhanced MRI in patients with inoperable liver cancer (SORAMIC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 16.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 16.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2009-012576-27-NLMedical Faculty, University Magdeburg665